Low molecular weight heparin fraction PK 10169: a new therapeutic means for anticoagulant therapy?
To test the efficacy and safety of low molecular weight heparin (LMWH) fractions in thromboembolic diseases, 2 pilot studies were performed. The aim of the first was to test the antithrombotic efficacy of the LMWH PK 10169 (Pharmuka Laboratories) in 9 patients (group I) with acute pulmonary embolism documented by pulmonary angiography and scintiscan. The second study was intended to test the safety of the same LMWH fraction in a group (group II) of 30 patients at high risk of bleeding but also requiring antithrombotic therapy. In the 2 groups, the antithrombotic efficacy of PK 10169 was found to be excellent: no recurrence of pulmonary embolism was noted in group I and no thrombotic event occurred in group II. Neither side effects nor major bleeding complications occurred in either group. However, 1 patient in group II had a moderate bleeding in relation to a transient overdosage, and 3 others exhibited minor bleeding which did not necessitate dosage adjustment. In these studies, PK 10169, at the dosage used, proved an effective antithrombotic therapy with few side effects even in a group of patients considered to be at high risk of bleeding.
Huet
Y
Y
Gouault-Heilmann
M
M
D000328:Adult; D000368:Aged; D000925:Anticoagulants; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013927:Thrombosis / Q000188:drug therapy* / Q000517:prevention & control
D000925:Anticoagulants; D006493:Heparin